Related by context. All words. (Click for frequent words.) 68 novel oral tubulin 65 RGB # 64 OXi# 64 ganetespib 64 R roscovitine 63 Tesetaxel 63 XL# anticancer compounds 63 CORT # 63 INCB# [001] 63 alvespimycin 63 CYT# potent vascular disrupting 62 Perifosine 62 non nucleoside HCV 62 albiglutide 62 PXD# 62 orally administered inhibitor 62 Xanafide 62 AAG geldanamycin analog 62 tezampanel 62 acyclovir Lauriad R 62 PI3K/Akt pathway inhibitor 62 clinical trials Archexin ® 61 CD# CEA 61 evaluating mipomersen 61 Cloretazine ® 61 tesetaxel 61 TKB# 61 selective androgen receptor modulator 61 cMET 61 telomerase therapeutic 61 torezolid phosphate 61 recurrent metastatic ovarian cancer 61 PEG Interferon lambda 60 Exelixis compounds 60 multi kinase inhibitor 60 ocular formulation 60 leading oral taxane 60 SAR# [004] 60 oral isoform selective HDAC 60 OncoVEX GM CSF 60 VEGFR2 inhibitor 60 YONDELIS 60 novel VDA molecule 60 oral proteasome inhibitor 60 JAK inhibitors 60 generation proteasome inhibitor 60 XL# XL# XL# 60 drug pipeline TAFA# 60 Ophena TM 60 dependent kinase inhibitor 60 MKC# MKC# PP 60 MGCD# [001] 60 lintuzumab SGN 60 IMC #B 60 lenalidomide Revlimid R 60 Exherin TM 59 IAP inhibitor 59 MKC# MT 59 IMC A# 59 ENMD # 59 HGS ETR2 59 R#/MEM # 59 TAFA# 59 Imetelstat 59 Atiprimod 59 mGluR5 negative 59 XL# XL# XL# XL# 59 oral picoplatin 59 Serdaxin ® 59 TRAIL receptor antibodies 59 receptor tyrosine kinase inhibitor 59 novel topoisomerase 59 Oral NKTR 59 Panzem R 59 Solazed TM 59 PSMA ADC 59 AKT inhibitor 59 Romidepsin 59 multitargeted 59 vascular disrupting agent 59 MCSP respectively 59 HGS ETR1 59 delta opioid receptor 59 studies evaluating satraplatin 59 oral prodrug 59 TRIOLEX ™ 59 cardiac myosin activator omecamtiv 59 Synavive 59 immunosuppressive compound 59 including eniluracil ADH 59 Phase #b/#a clinical 59 HepeX B TM 59 candidate CRLX# 58 demonstrated antitumor activity 58 cancer indications bafetinib 58 HGS# 58 Archexin 58 PDE4 inhibitor 58 PSN# [002] 58 Carfilzomib 58 telomerase inhibitor drug 58 HCD# [002] 58 PEG SN# 58 Sym# 58 Elagolix 58 CDK cyclin dependent 58 MEK Inhibitor 58 myelofibrosis polycythemia vera 58 Panzem R NCD 58 investigational monoclonal antibody 58 novel tubulin binding 58 Glufosfamide 58 Bayer HealthCare Onyx Pharmaceuticals 58 Epothilone D 58 NGX# 58 trastuzumab DM1 T DM1 58 metaglidasen 58 angiotensin analog 58 oral nucleoside analogue 58 docetaxel Taxotere R 58 Aflibercept 58 PLK1 SNALP 58 Daclizumab 58 Phase Ib study 58 Lenocta 58 LEVADEX TM 58 GRN#L 58 investigational humanized monoclonal antibody 58 malignant mesothelioma Alfacell 58 Budesonide foam crofelemer 58 PRX # 58 HGS ETR1 mapatumumab 58 mertansine 58 evaluating tivozanib 58 Inovio clinical 58 Pharmos pipeline 58 sorafenib tablets 58 Phase Ib clinical trials 58 Phase IIa trials 58 Phase 1b clinical trials 58 BRIM2 58 GetGoal Phase III 58 PORxin TM platforms 58 non nucleoside inhibitor 58 RDEA# 58 evaluating satraplatin 58 Omacetaxine 58 Hsp# Inhibitor 58 includes TOLAMBA TM 58 seliciclib CYC# 57 targeting refractory relapsing 57 Traficet EN 57 TÎ ² 4 57 HCV polymerase inhibitors 57 ONCONASE R 57 small molecule chemotherapeutic 57 HuMax EGFr 57 LHRH antagonists 57 integrin inhibitor 57 HCV NS5B polymerase 57 clinical trials SGN 57 PDX pralatrexate 57 sunitinib malate 57 REVIVE Diabetes 57 tubulin inhibitor 57 class mGluR5 inhibitor 57 proteasome inhibitor 57 Pivotal Phase III 57 blinded randomized placebo controlled 57 GALNS 57 XL# XL# 57 Rigel R# 57 Curaxin 57 agonistic human 57 OMP #M# 57 PS# [001] 57 products MKC# PP 57 tanespimycin 57 erlotinib Tarceva ® 57 LymphoStat B belimumab 57 forodesine 57 Symadex 57 dacetuzumab SGN 57 pralatrexate injection folate analogue 57 histone deacetylase HDAC inhibitor 57 evaluating Xcytrin 57 Lenocta TM 57 sodium thiosulfate STS 57 GVAX ® 57 Entereg R 57 APEX PD 57 Personalized Immunotherapy 57 novel histone deacetylase 57 Phase Ib II 57 JAK inhibitor 57 candidate AQ4N 57 sarcoma melanoma 57 lesinurad 57 CCX# 57 AP# [003] 57 Phase 2a clinical trials 57 ospemifene 57 MAGE A3 ASCI 57 phase IIb clinical 57 preclinical efficacy 57 obatoclax 57 SPP# [002] 57 next generation URAT1 57 Combo Stent 57 denosumab oncology 57 custirsen 57 atrial fibrillation budiodarone ATI 57 paclitaxel Taxol ® 57 SNT MC# 57 talactoferrin 57 kidney urologic 57 neratinib 57 IMA# 57 AVOREN 57 TBC# 57 #/#/# Cytokinetics Incorporated 57 JAK1 57 unique alkylating agent 56 Seliciclib 56 Phase IIb Trial 56 phase Ib 56 diagnostic molecular imaging 56 4SC AG ISIN DE# 56 LUVENIQ 56 liposomal formulation 56 Azedra ™ 56 synthetic cannabinoid library 56 dacetuzumab 56 Annamycin 56 huC# DM4 56 tramiprosate Alzhemed TM 56 Pharmos proprietary 56 axitinib 56 XP# XP# 56 OMNARIS HFA 56 GV# [001] 56 ThermoDox ® clinical 56 relapsed MM 56 clinical trials dacetuzumab SGN 56 Ofatumumab 56 CB2 selective receptor agonist 56 CTA# Injection 56 signal transduction inhibitor 56 generation URAT1 inhibitor 56 aflibercept VEGF Trap 56 Cannabinor 56 Phase Ib 56 KRN# 56 Sapacitabine 56 deforolimus 56 Crofelemer budesonide foam 56 MDV# 56 INxin TM 56 Randomized Double blind 56 TLR antagonists 56 2 inhibitor CYT# 56 Aplidin 56 MT# MEDI 56 ixabepilone 56 Quinamed 56 BRAF inhibitor 56 rheumatoid arthritis psoriasis 56 ASONEP 56 alpha folate receptor 56 R rilonacept Injection 56 OMP #R# 56 Prostate AdenoCarcinoma Treatment 56 Nuvelo Announces 56 generation Hsp# inhibitor 56 bazedoxifene conjugated estrogens 56 IDX# 56 ALS #-# 56 pertuzumab 56 CRx 56 pancreatic prostate 56 antiangiogenesis therapies 56 OncoVex 56 R roscovitine CDK cyclin 56 PDE4 modulators 56 phase III isavuconazole 56 OvaRex R 56 PMX # heptagonist 56 highly selective inhibitor 56 sapacitabine CYC# 56 oral chemotherapeutic agent 56 ADP receptor antagonist 56 serine protease inhibitor CU# 56 Mipomersen 56 sunitinib Sutent ® 56 trastuzumab Herceptin R 56 Empatic ™ 56 AQ4N 56 Cloretazine R VNP#M 56 Pivotal Phase 56 AVE# 56 plus prednisone prednisolone 56 NVA# 56 clinical trials Archexin 56 Allovectin 7 R 56 relapsed multiple myeloma 56 oral ridaforolimus 56 dimebon latrepirdine 56 pivotal bioequivalence 56 MYDICAR ® 56 MAXY alpha 56 5 HT2A inverse 56 phase IIa 56 tezampanel NGX# 56 ongoing Phase IIIb 55 GLP toxicology studies 55 vinca alkaloid 55 Virulizin ® 55 CYT# vascular disrupting 55 Pazopanib 55 Curaxin CBLC# 55 Imprime PGG 55 HDAC Inhibitor 55 Prodarsan ® 55 Phase 1a clinical 55 TRIOLEX HE# APOPTONE HE# 55 Phase Ib clinical 55 Cloretazine 55 CYP#A# CYP#D# 55 DNA methyltransferase inhibitors 55 adipiplon 55 phase IIb 55 sapacitabine 55 hypoxia activated prodrug 55 Genasense oblimersen sodium Injection 55 investigational protease inhibitor 55 small molecule glucokinase 55 tiapamil 55 voreloxin 55 solid tumors ZYBRESTAT 55 RAS MAPK pathway 55 Phase III Pivotal 55 Fovea Pharmaceuticals subsidiary 55 solithromycin 55 lexidronam injection 55 vaccines oncolytic virus 55 Aplidin R 55 advanced carcinoid 55 antibody MAb 55 MGd 55 nucleoside polymerase inhibitor 55 initiate Phase 1b 55 catheter occlusion CO 55 riociguat 55 Tarceva TM 55 apoptosis inducer 55 TELINTRA 55 EXPLORE Xa 55 midstage clinical 55 LX# LX# 55 Cetrorelix 55 sodium glucose cotransporter 55 PF # [001] 55 elotuzumab 55 prokinetic agent 55 NXL# 55 LEVAQUIN ® 55 cancer immunotherapies 55 PANVAC VF 55 BHT DNA 55 IMiDs ® 55 docetaxel Taxotere ® 55 ceftazidime 55 targeted protein kinase 55 Tyrima 55 lintuzumab 55 PRT# 55 oncolytic virus therapies 55 Allovectin 7 55 visilizumab 55 Telik logo TELINTRA 55 dosing cohort 55 IMGN# 55 Zemiva ™ 55 mocetinostat MGCD# 55 ANYARA 55 Cintredekin Besudotox 55 FOLOTYN ® 55 PD LID 55 Selzentry Celsentri 55 CRLX# 55 Afatinib 55 palifosfamide Zymafos TM 55 tribulations Groenveld 55 BCX# 55 BiTE antibodies targeting 55 FOLFOX6 chemotherapy regimen 55 recombinant PSMA vaccine 55 Neulasta ® 55 EQUIP OB 55 AzaSite Plus 55 oral rivaroxaban 55 Excellarate TM 55 Phase 2a Clinical Trial 55 multicenter Phase III 55 Elotuzumab 55 Bezielle 55 Panzem NCD 55 vidofludimus 55 Phase IIa clinical trials 55 adecatumumab MT# 55 Proellex TM 55 MAP# 55 Second Pivotal Phase 55 adhesion molecule EpCAM expressing 55 observer blinded randomized 55 ZYBRESTAT fosbretabulin 55 acetylgalactosamine 6 55 CBLC# 55 Obatoclax 55 nilotinib Tasigna ® 55 Phase 2b Clinical Trial 55 development peramivir neuraminidase 55 TACI Ig 55 virus HCV protease inhibitor 55 adecatumumab 55 imetelstat GRN#L 55 Saforis 55 sirtuin modulators 54 orally bioavailable 54 Acetavance TM intravenous acetaminophen 54 liver cancers hypercholesterolemia 54 HDAC inhibition 54 galiximab 54 Tekamlo 54 ritonavir boosted danoprevir 54 targeting miR 54 BAY #-# 54 CCR5 antagonist 54 Phase IIb trials 54 Pimavanserin 54 Kahalalide F 54 SUTENT ® 54 Guanilib 54 Testosterone MDTS R 54 Completes Patient Enrollment 54 Omnitarg 54 Edurant 54 placebo controlled Phase 54 IMiDs R 54 dasatinib Sprycel 54 mGluR2 positive 54 TransVax TM 54 AML MDS 54 Aztreonam lysine 54 product platforms AZX# 54 investigational pan BCR 54 Tofacitinib 54 Phenoptin 54 R#/MEM 54 cannabinor 54 PRTX 54 Alagebrium 54 pan HDAC inhibitor 54 mda 7 54 evaluating picoplatin 54 paclitaxel Taxol 54 Combivir Kivexa 54 cediranib 54 CEQ# 54 Randomized Phase 54 Thorough QT Study 54 Trofex 54 rALLy clinical trial 54 QUADRAMET R 54 Albuferon TM 54 Azedra 54 AeroLEF TM 54 certain protein tyrosine 54 cathepsin K inhibitor 54 reslizumab 54 ISIS # 54 LymphoStat B TM 54 CAMMS# 54 dasatinib Sprycel ® 54 Allovectin 7 ® 54 SAR# [002] 54 Ceflatonin R 54 preclinical toxicology 54 TORISEL TM 54 PrevOnco ™ 54 VEGF inhibitors 54 DCVax R 54 AEG# 54 sorafenib Nexavar ® 54 ® bortezomib 54 var arrContent = 54 KNS # 54 Hyphanox 54 ARRY # 54 SparVax TM 54 www.telik.com 54 HCV antiviral 54 brand ciclesonide HFA 54 Troxatyl 54 docetaxel Taxotere 54 enzastaurin 54 include GALNS N 54 Vaxfectin TM 54 PROSTVAC TM 54 ragweed allergy immunotherapeutic 54 sorafenib Nexavar R 54 dosing cohorts 54 Initiates Enrollment 54 Initiated Phase 54 Adnectin 54 polymerase inhibitor 54 NABTT 54 Kinesin Spindle Protein KSP 54 MLN# 54 rNAPc2 54 tumor xenograft models 54 QLT# 54 Pertuzumab 54 ZFP Therapeutics 54 Triolex 54 anticancer compound 54 DermaVir Patch 54 initiated Phase Ib 54 fosbretabulin 54 R sorafenib tablets 54 Hematide ™ 54 Medullary Thyroid Cancer 54 CCR2 receptor 54 Ocrelizumab 54 Phase IIb Clinical Trial 54 crizotinib PF # 54 humanized monoclonal antibody 54 bevacizumab Avastin ® 54 Factor VIIa 54 Phase Ib IIa 54 registrational studies 53 preclinical 53 Taxanes 53 DDP# 53 gastrointestinal disorders ATI 53 gemcitabine Gemzar 53 IND enabling 53 subcutaneous Herceptin 53 placebo controlled Phase III 53 Phase #/#a trial 53 BRIM3 53 Trastuzumab DM1 53 PROVENGE ® 53 CUDC 53 Deforolimus 53 ORAL Solo 53 IIa clinical 53 #D#C# 53 TRANSDUR ® 53 SinuNase ™ 53 Methylnaltrexone 53 Myocet 53 SYN# 53 refractory metastatic 53 sorafenib Nexavar 53 PHX# 53 laquinimod 53 pomalidomide 53 severe hypercholesterolemia 53 Initiates Phase II 53 Phase III placebo controlled 53 developing Bicifadine serotonin 53 phase 2a 53 EndoTAG TM -1 53 advanced metastatic prostate 53 SIRT1 activators 53 LEP ETU 53 Gabapentin GR 53 trial evaluating PRX# 53 Alocrest 53 Amigal 53 rilonacept Injection 53 compound INCB# 53 Additionally Nexavar 53 EOquin 53 lead Aganocide compound 53 Actilon 53 vosaroxin 53 Vitaxin 53 protein kinase inhibitor 53 THR beta agonist 53 PrevOnco 53 EGFR HER2 53 DGAT1 inhibitors 53 LBH# 53 ERBITUX dermatologic toxicities 53 anti PlGF 53 relapsed refractory multiple myeloma 53 Zemplar Capsules 53 ATL# [001] 53 rheumatoid arthritis psoriatic arthritis 53 cilengitide 53 highly selective endothelin 53 torsemide ER 53 SCH # 53 fostamatinib 53 intravesical infusion therapy 53 irinotecan doxorubicin oxaliplatin paclitaxel 53 colorectal bladder 53 catheter occlusion 53 recombinant biopharmaceutical 53 VNP#M 53 candidates Augment ™ 53 phase IIb trial 53 randomized controlled multicenter 53 Exelixis XL# 53 registrational Phase 53 CA4P 53 GRNVAC1 53 tyrosine kinase inhibitor 53 brentuximab vedotin SGN 53 Romiplostim 53 ALN HTT 53 Ostarine 53 ABL inhibitor 53 modulate ion channels 53 IIa trial 53 HuLuc# 53 cutaneous T cell 53 6 sulfatase 53 JAK2 Inhibitor 53 eltrombopag 53 APTIVUS r 53 Zemiva TM Trofex TM 53 Novel Oral 53 MKC# PP 53 CR# vcMMAE 53 PEGylated interferon 53 Meets Primary Endpoint 53 relapsed myeloma 53 Zemiva TM 53 TransVax ™ 53 Initiate Phase 53 Trofex TM 53 Allovectin 7 r 53 2 methoxyestradiol 53 Testosterone MDTS ® 53 UPLYSO 53 developing ostarine selective 53 generation purine nucleoside 53 androgen receptor modulator 53 Vicriviroc 53 Selective Electrochemical Tumor Ablation 53 XL# [003] 53 RhuDex 53 Asentar 53 Lucanix R 53 PEG PAL 53 ongoing Phase 1b 53 Phase IIB 53 specific CCR9 antagonist 53 Fibrillex TM 53 gastric pancreatic 53 Clonicel 53 romazarit 53 metastatic castrate resistant 53 anionic backbone 53 ATAC Arimidex Tamoxifen Alone 53 Resten NG 53 INCB# [002] 53 REGN# 53 confirmatory clinical 53 TRAIL receptor antibody mapatumumab 53 Phase III Trials 53 vapreotide acetate 53 Ovitrelle R Serostim 52 dose escalation Phase 52 Civacir 52 Lu AA# 52 Skinvisible receives 52 Phase lll 52 Pralatrexate 52 GEM OS2 52 PREOS R 52 Phase 2b clinical trials 52 APTIVUS ritonavir 52 MOZOBIL 52 SinuNase TM 52 Combination REOLYSIN R 52 eniluracil 52 Neuvenge 52 candidates Azedra TM 52 Evaluation Program CTEP 52 NP2 Enkephalin 52 memantine HCl 52 phase IIa clinical 52 orally dosed 52 Completes Enrollment 52 ATRA IV 52 immunotherapeutic approaches 52 standard chemotherapy regimens 52 octreotide implant 52 HIV integrase inhibitor 52 Fx #A 52 Phase 1b Clinical Trial 52 mitogen activated ERK kinase 52 var arrUrl = 52 Phase 2a 52 oral opioid modulator 52 Albuferon Phase 52 ANCHOR trial 52 PREZISTA r 52 AEGR 52 ZFP Therapeutic 52 GLPG# 52 novel oral anticoagulant 52 var arrMeta = 52 histologies 52 oral antiviral 52 Initiates Phase 52 oral calcitonin licensed 52 preclinical studies 52 Genentech Boehringer Ingelheim 52 tamibarotene 52 velafermin 52 romidepsin novel 52 confirmatory pivotal 52 oral taxane 52 Xcellerated T Cells 52 selective estrogen receptor modulator 52 herpetic keratitis 52 Histone Deacetylase 52 ADVANCE PD 52 anthracycline taxane 52 ALGRX 52 ularitide 52 CTAP# Capsules 52 Vidaza R 52 Phase III metastatic melanoma 52 registrational 52 MERLIN TIMI 52 Advaxis Phase 52 nab paclitaxel 52 EOquin TM phase 52 diabetic neuropathic pain 52 talabostat 52 colorectal lung 52 psoriasis rheumatoid arthritis 52 midstage clinical trials 52 non constipating irritable 52 metastatic colorectal 52 alfa 2a 52 Locteron ® 52 monoclonal antibody IgG1 Mab 52 regarding Aethlon Medical 52 RhuDex ® 52 trastuzumab emtansine T DM1 52 GAMMAGARD 52 radiation chemoradiation 52 OvaRex ® MAb 52 Urocidin 52 Phase #b/#a trial 52 Cardiotoxicity 52 investigational HCV polymerase 52 Accelerating apoptosis may 52 Phase 1b 52 Tarvacin Anti Cancer 52 GATTEX ® 52 dextromethorphan quinidine 52 Androxal TM 52 Hormone Refractory Prostate Cancer 52 Lisofylline LSF 52 Initiates Clinical 52 Onconase 52 Mg Usa 52 rheumatoid arthritis thrombocytopenia 52 Thorough QT 52 sulfonylurea glimepiride 52 TG# [003] 52 pentadentate logo R 52 aclidinium 52 MKC# 52 SUCCEED trial 52 mg q#h 52 Phase III Clinical Trial 52 BOLDER II 52 Luveris R Ovidrel R 52 Pegasys ® 52 ponatinib 52 Teriflunomide 52 IIb clinical trial 52 Immunotherapeutic 52 mTOR inhibitors 52 LEVADEX 52 mGluR5 NAM 52 confirmatory Phase 3 52 evaluating T DM1 52 perifosine 52 PhG alpha 1 52 Phase #/#a 52 INSPIRE Trial Phase III 52 ALKS 52 Phase IIb clinical trials 52 TMC# [002] 52 Amrubicin 52 NEUGENE antisense 52 granted Ortec 52 midstage trials 52 peripherally acting 52 IL# PE#QQR 52 volociximab 52 Ozarelix 52 CHAMPION PCI 52 romidepsin 52 HMG CoA reductase inhibitors 52 Optiquel ™ 52 squalamine 52 DEB# 52 aurora kinase 52 randomized discontinuation trial 52 EnVivo Pharmaceuticals Inc. 52 IIa clinical trials 52 OLpur TM H2H 52 non personalized allogeneic 52 cisplatin gemcitabine 52 perifosine KRX 52 danoprevir 51 pramlintide metreleptin 51 saquinavir ritonavir 51 ILUVIEN ® 51 Vidaza ® 51 teriflunomide 51 interferon gamma 1b 51 candidate iSONEP TM 51 tolevamer 51 pan histone deacetylase 51 verdict elicited gasps 51 Aurexis 51 ALD# 51 PRECISE Trial 51 ALN VSP Phase 51 ThermoDox R 51 Successfully Completes Phase 51 severe hypersensitivity reactions 51 phase IIb study 51 sNDA submission 51 patients oral indibulin 51 Dacogen injection 51 Targretin capsules 51 severe degenerative ischemic 51 pegylated interferons 51 Pruvel TM 51 Brentuximab Vedotin SGN 51 ALN HPN 51 Phase IIIb clinical 51 Augment TM 51 Triapine R 51 dyskinesia PD LID 51 Xeloda capecitabine 51 docetaxel chemotherapy 51 ZD# [001] 51 Luramist TM 51 PEGylated irinotecan 51 isolated hypertriglyceridemia 51 potentially hepatotoxic 51 Bioral Amphotericin B 51 investigational oral 51 dexpramipexole 51 TELCYTA 51 Imprime PGG ® 51 Xeloda ® 51 bapineuzumab AAB 51 ASG 5ME dacetuzumab SGN 51 LibiGel ® 51 commercialize CorMedix drug 51 velafermin belinostat 51 huN# DM1 51 refractory gout 51 Zenvia Phase III 51 REVIVE TA 51 bendamustine 51 EGS# 51 trodusquemine 51 arsenic trioxide injection 51 UVIDEM 51 oral methylnaltrexone 51 familial amyloidotic polyneuropathy FAP 51 Fludara ® 51 MEND CABG 51 generation calcineurin inhibitor 51 BEMA Buprenorphine 51 ® decitabine 51 Xelox 51 Delta opioid receptor 51 Laquinimod 51 rheumatoid arthritis juvenile idiopathic 51 Solazed 51 adenosine injection 51 multicenter dose escalation 51 inflammatory autoimmune diseases 51 Phase 2b clinical 51 ZYBRESTAT 51 RhuDex R 51 elagolix 51 Qnexa TM 51 MDS AML 51 mapatumumab 51 CG# oncolytic virus 51 biologic DMARD 51 PEGylated docetaxel 51 novel antimitotic agent 51 SLx 51 phase Ib clinical 51 mGluR2 NAM 51 coagulation factor VIIa 51 rALLy trial 51 system REG1 consists 51 Pharming website http:/www.pharming.com 51 NS5B polymerase 51 cosmetic cosmeceutical products 51 5 FU leucovorin 51 AZD# 51 overactive bladder AA# 51 dose limiting toxicities 51 NuroPro ® 51 XL# SAR# 51 rhIGFBP 3 51 ACAPODENE 51 Dyloject TM 51 metastatic hormone refractory 51 eosinophilic asthma 51 PREZISTA rtv 51 MEK inhibitor RDEA# 51 GVAX R 51 Shigamabs ® 51 ELACYT 51 Planetwide Media My 51 VICTOR E1 51 chemotherapeutic regimens 51 OHR/AVR# 51 Phase II 51 BENLYSTA ® 51 Phase 2a clinical 51 novel peptides 51 investigational compound 51 CCR5 mAb 51 pharmacodynamic properties 51 thalidomide Thalomid 51 elacytarabine 51 azilsartan medoxomil 51 Targeted Chemotherapy 51 adalimumab Humira 51 ZOLINZA 51 VEGF Trap 51 evaluating bafetinib 51 StemEx 51 low dose cytarabine 51 estramustine 51 GSK# [001] 51 gemcitabine Gemzar ® 51 DOS# 51 ACTEMRA 51 dose escalation phase 51 carfilzomib 51 Litx 51 cortisol synthesis 51 Biogen Genentech 51 dirucotide MBP# 51 Intervention Effectiveness 51 Canvaxin TM 51 NuroPro R 51 HuMax CD# 51 pancreatic colon 51 PI3K Akt 51 pharmacogenomic translational research 51 dose cohorts 51 DIRECT Trial 51 BLA submission 51 dexamethasone Decadron 51 AE# vaccine 51 progressive metastatic prostate 51 opioid induced bowel dysfunction 51 Luveniq 51 ™ testosterone gel 51 LightCycler ® Instrument 51 REG1 51 ToGA 51 RSD# oral 51 solanezumab 51 farletuzumab 51 regorafenib 51 Contrave# 51 both intercalates DNA 51 European Sepsis Trial 51 MAbs targeting 51 placebo controlled clinical 51 BiTE R 51 SIMCOR ® 51 pharmacokinetics pharmacodynamics